NCT00928902View on ClinicalTrials.gov

Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With High Risk Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

November 30, 1999

Primary Completion Date

April 30, 2001

Study Completion Date

March 31, 2005

Conditions
Melanoma
Interventions
DRUG

low-dose IL-2

low-dose IL-2, administered daily for 6 weeks, to begin either at week 1 (group 1) or week 4 (group 2)

BIOLOGICAL

melanoma vaccine

six melanoma vaccines given over a 6-week period

All Listed Sponsors
lead

University of Virginia

OTHER